Tiziana Life Sciences has announced plans for development of its foralumab intranasal anti-CD3 monoclonal antibody for two additional indications, Type 1 diabetes and Alzheimer’s disease. Tiziana said that it is initiating a development program for diabetes and that it plans to submit an IND for clinical development of foralumab in patients with Alzheimer’s in the second quarter of this year.
The company recently announced plans for a Phase 2 trial of intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis and said that it would develop foralumab for the treatment of hemorrhagic stroke and long COVID.
Tiziana Executive Chairman and interim CEO Gabriele Cerrone commented, “With the FDA approval of the humanized anti-CD3 mAb TZIELD (teplizumab-mzwv injection) and then its subsequent announced acquisition of Provention Bio by Sanofi for $2.9 billion, CD3 has emerged as an established and attractive target for Type 1 Diabetes. We believed that having a fully human CD3 antibody may offer benefits to patients across many different chronic disease indications.”
Regarding the Alzheimer’s program, Cerrone said that the company plans to apply for $3 million in funding “from a prestigious Alzheimer’s foundation” for a Phase 2a trial and expects to hear whether that application is successful by the third quarter of 2023.
Read the Tiziana Life Sciences press release on foralumab for diabetes.
Read the Tiziana Life Sciences press release on foralumab for Alzheimer’s disease.
